Dupixent Lawsuit in West Virginia

The short answer is yes — and the science behind it is alarming. A peer-reviewed study of 19,612 patients found that Dupixent users face a 4.5 times higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to people who never took the drug. To put that in perspective, a 4.5x relative risk is in the same ballpark as the asbestos-mesothelioma association that drove one of the largest mass tort litigations in American history. The proposed biological mechanism is straightforward and troubling. Dupixent blocks two signaling molecules — IL-4 and IL-13 — that are part of the type 2 immune response. Blocking these signals is what makes the drug effective against eczema and asthma. But those same signals appear to play a role in immune surveillance against T-cell malignancies. By suppressing them, Dupixent may release the brakes on pre-malignant T-cell clones that the immune system had been keeping in check. The result: a cancer that literally disguises itself as the disease the drug is supposed to treat. The FDA placed Dupixent on its safety watchlist in March 2025 and escalated to a formal investigation in September 2025 after receiving more than 300 adverse event reports related to lymphoma and blood cancers. As of April 2026, the investigation is ongoing. Regeneron and Sanofi have not added a specific CTCL warning to the Dupixent label.

Cutaneous T-cell lymphoma is a cancer of the immune system that begins in the skin. Specifically, T-lymphocytes — white blood cells that are supposed to protect you from infections and abnormal cells — become malignant and accumulate in the skin, forming patches, plaques, and eventually tumors. The most common subtype is mycosis fungoides, which can remain indolent for years or progress to Sezary syndrome, an aggressive form where cancer cells circulate through the bloodstream. The connection to Dupixent lies in the drug's mechanism of action. Dupixent works by blocking IL-4 and IL-13 — two signaling molecules that drive type 2 inflammation. But these molecules also appear to play a role in keeping abnormal T-cells under control. When Dupixent shuts down that pathway, it may allow pre-existing T-cell clones with malignant potential to proliferate unchecked. Researchers describe this as an 'unmasking' effect — the cancer was there, but the immune system was holding it back. Dupixent may remove that restraint. The most dangerous aspect of this connection is diagnostic mimicry. Early CTCL looks almost identical to eczema — red, scaly patches on the skin. For a patient taking Dupixent for eczema, new skin lesions are almost always attributed to eczema flares rather than cancer. This can delay diagnosis by months or years, allowing the cancer to progress to stages where treatment options narrow and survival rates drop sharply.

If you took Dupixent for any condition — atopic dermatitis, asthma, chronic sinusitis, COPD, or any other indication — and were subsequently diagnosed with cutaneous T-cell lymphoma (including mycosis fungoides or Sezary syndrome), you may have a valid claim. There is no minimum duration of Dupixent use required. Some reported cases involve patients who developed CTCL after relatively short treatment periods, which is consistent with the unmasking theory: if Dupixent releases the brakes on a pre-existing malignancy, the cancer can manifest quickly. Family members of people who died from CTCL or T-cell lymphoma after Dupixent use may be eligible to file wrongful death claims. You do not need to have stopped taking Dupixent — active patients with a CTCL diagnosis can file while still receiving treatment for their cancer. The key requirements are documentation of Dupixent use (pharmacy records, insurance claims, or medical records), a confirmed CTCL or T-cell lymphoma diagnosis (pathology report with biopsy confirmation), and filing within your state's statute of limitations. A free consultation with a mass tort attorney can determine whether your specific circumstances support a claim. Consultations are confidential, and most Dupixent attorneys work on contingency — fee terms vary by attorney.

As of April 2026, all federal Dupixent lawsuits alleging cancer injuries have been consolidated into Multidistrict Litigation No. 3180 by the Judicial Panel on Multidistrict Litigation. The MDL is in its earliest procedural stages — the court has appointed a plaintiffs' steering committee, and initial case management orders are being issued. Discovery has not yet begun in earnest, but attorneys expect the first round of document requests to target Regeneron's internal safety data, communications with the FDA, and pharmacovigilance records. No settlements have been reached and no cases have gone to trial. The litigation follows a well-established pattern for pharmaceutical MDLs: after discovery is substantially complete, the court will select bellwether cases for trial. Bellwether verdicts — typically the first three to five cases tried — establish the litigation's settlement value and create pressure for global resolution. This process typically takes two to four years from MDL formation, meaning bellwether trials could begin in 2028 or 2029. Separately, the FDA's formal investigation into Dupixent's cancer risk remains ongoing. Any regulatory action — particularly a boxed warning or label change requiring specific CTCL risk disclosure — would significantly strengthen plaintiffs' cases and could accelerate settlement discussions.

It is too early to provide specific settlement projections for Dupixent cases because no settlements or verdicts have been reached. But we can look at comparable pharmaceutical cancer litigations to understand the range of possibilities. In the Roundup litigation, individual settlements for non-Hodgkin lymphoma ranged from approximately $100,000 to over $2 million depending on cancer severity and treatment burden. Bayer ultimately paid over $10 billion to resolve approximately 100,000 claims. For Dupixent, case values will likely be stratified by the severity of the CTCL diagnosis. Early-stage mycosis fungoides managed with skin-directed therapies may fall in the $75,000 to $200,000 range. Advanced CTCL requiring chemotherapy, radiation, or targeted biologic therapy could be valued at $200,000 to $1 million. Wrongful death cases and terminal diagnoses — particularly Sezary syndrome and large cell transformation — could exceed $2 million. One factor that may favor Dupixent plaintiffs is the strength of the epidemiological evidence. A 4.5x relative risk is considered highly significant in both medical research and legal causation standards. The Daubert challenge to plaintiffs' expert testimony — often the most contentious phase of pharmaceutical MDLs — may be less of an obstacle than in litigations with weaker statistical associations.

This is the central question in Dupixent litigation — and the answer will emerge from discovery as the MDL progresses. What we know publicly is this: adverse event reports linking Dupixent to lymphoma and blood cancers had been accumulating in the FDA Adverse Event Reporting System (FAERS) for years before the formal investigation. The scientific literature on IL-4/IL-13 pathway disruption and immune surveillance against T-cell malignancies was available to Regeneron's and Sanofi's research scientists at the time of approval and throughout the post-market period. Plaintiffs allege that the manufacturers engaged in inadequate pharmacovigilance — that they failed to investigate the cancer signal with the urgency that the data warranted, and that they failed to update the drug's label to warn specifically about CTCL risk. The current Dupixent label mentions the possibility of malignancies in general terms, but does not specifically warn about cutaneous T-cell lymphoma or the diagnostic confusion that arises from prescribing an eczema drug that can cause a cancer mimicking eczema. If discovery reveals internal documents showing that Regeneron or Sanofi were aware of the CTCL signal and chose not to act — or that they deliberately framed CTCL reports as eczema treatment failures in their pharmacovigilance databases — it could dramatically increase both liability and damages, including potential punitive damages.

Yes — you do not need to stop taking Dupixent to file a lawsuit. If you have been diagnosed with CTCL or another T-cell lymphoma while using or after using Dupixent, your legal claim exists regardless of whether you continue the medication. The decision to stop or continue Dupixent is a medical decision that should be made with your treating physician, not your attorney. Some patients with severe atopic dermatitis or asthma have no adequate alternative treatments, and stopping Dupixent could cause significant health deterioration. That said, if you have a confirmed CTCL diagnosis, your oncologist will almost certainly recommend discontinuing Dupixent — continuing a drug that may be promoting T-cell malignancy while simultaneously undergoing cancer treatment is medically counterproductive. The important thing is to make this decision in consultation with your medical team, not based on legal strategy.

The distinction matters because it directly affects how much you can recover. In a class action, all members share a single settlement pot — often resulting in relatively small per-person payments. In a multidistrict litigation (MDL), each plaintiff maintains their own individual case with their own specific facts, damages, and potential recovery. The MDL structure simply consolidates the pretrial process — discovery, expert challenges, and procedural motions — before a single judge for efficiency. In MDL No. 3180, your case is uniquely yours. A patient diagnosed with early-stage mycosis fungoides managed with topical therapy will have a different case value than a patient who underwent chemotherapy for Sezary syndrome or whose family filed a wrongful death claim. The MDL process allows the court to handle common legal issues efficiently while preserving each plaintiff's right to individual assessment and compensation based on their specific circumstances. After bellwether trials establish settlement benchmarks, most MDLs move toward global resolution — a structured settlement program in which individual case values are assigned based on severity tiers, treatment burden, and other case-specific factors. Plaintiffs who are unsatisfied with their assigned value retain the right to opt out and pursue individual trial.

The evidence you need falls into two categories: proof of Dupixent use and proof of cancer diagnosis. For Dupixent use, the strongest evidence includes pharmacy dispensing records showing when you filled your prescriptions, insurance claims showing Dupixent charges, medical records with prescribing notes, and injection logs from your doctor's office or specialty pharmacy. Even partial records are useful — your attorney can subpoena pharmacy records and insurance claim histories to fill gaps. For your cancer diagnosis, the essential document is your pathology report from the skin biopsy that confirmed CTCL or mycosis fungoides. The report should include the histopathological findings, immunohistochemistry results (CD3+, CD4+, loss of CD7/CD26), and ideally T-cell receptor gene rearrangement results confirming clonality. Your oncology treatment records — including staging workups, PET scans, chemotherapy regimens, and radiation plans — document the severity and treatment burden that drive your case value. You do not need to have all of this documentation organized before consulting an attorney. Most mass tort firms have medical record retrieval teams that gather and organize evidence as part of case preparation. The most important step is to preserve what you have — do not discard Dupixent packaging, pharmacy receipts, or medical records.

Yes — and this is more common than you might think. Many treating physicians are not yet aware of the epidemiological data linking Dupixent to CTCL, or they may be reluctant to attribute a rare cancer to a widely prescribed medication. Your doctor's clinical opinion is important for your medical care, but it is not determinative of your legal claim. In mass tort litigation, causation is established through expert testimony from epidemiologists, toxicologists, and oncologists who analyze population-level data and biological mechanisms. The 4.5x relative risk from the 19,612-patient study provides strong statistical support for general causation — the question of whether Dupixent can cause CTCL in the population. Specific causation — whether Dupixent caused your particular CTCL — is then established through expert analysis of your medical records, treatment timeline, and the absence of alternative explanations. An expert who reviews your chart and finds that you had no CTCL risk factors before Dupixent use, developed CTCL during or after treatment, and had a clinical presentation consistent with drug-induced T-cell lymphoma can provide a compelling specific causation opinion regardless of what your treating physician believes.

This is a medical decision, not a legal one — and it should be made in consultation with your prescribing physician. Abruptly stopping Dupixent can cause severe rebound flares of atopic dermatitis or worsening of asthma that may require emergency treatment. Your doctor can evaluate your individual risk factors, discuss the emerging safety data, and consider whether alternative treatments are appropriate for your situation. What we do recommend is vigilance. If you are currently taking Dupixent, discuss the CTCL risk with your dermatologist and ask about a monitoring protocol. Any new or changing skin lesions — particularly patches that look different from your usual eczema, lesions in unusual locations like the buttocks or trunk, or skin changes that do not respond to standard eczema treatments — should prompt a biopsy rather than an assumption that it is just another flare. Early detection of CTCL, if it develops, dramatically improves outcomes. If you are diagnosed with CTCL, your oncologist will almost certainly recommend stopping Dupixent immediately. At that point, the medical and legal decisions align: you need cancer treatment, and continuing a drug suspected of promoting that cancer serves no purpose.

Pharmaceutical MDLs are not quick — and anyone promising a fast resolution is not being honest. Based on the typical trajectory of comparable pharmaceutical cancer MDLs, the Dupixent litigation will likely follow this general timeline: 2026 to 2027 for discovery and expert development; 2027 to 2028 for Daubert challenges (where the court decides whether plaintiffs' and defendants' expert witnesses may testify); and 2028 to 2029 for bellwether trials — the first cases to go to trial. If bellwether verdicts favor plaintiffs, global settlement negotiations typically follow within 12 to 18 months. The realistic expectation for most plaintiffs is a resolution timeline of three to five years from the date of MDL formation — meaning 2029 to 2031 for the bulk of cases. Some cases may resolve sooner if early bellwether results are strongly in plaintiffs' favor and the defendants choose to negotiate rather than face repeated trial losses. The Roundup litigation, for comparison, produced its first plaintiff verdict in 2018 and Bayer announced a $10 billion settlement framework in 2020 — a two-year bellwether-to-settlement cycle. Early filing matters because cases filed early are most likely to be considered for bellwether selection, and bellwether plaintiffs often receive the highest individual recoveries. Filing early also ensures that your evidence is preserved, your medical records are secured, and your case is well-developed by the time settlement discussions begin.